In the first quarter, we made a full sum of the past ten years, “the first share of sphygmomanometer” Andon Health Co.Ltd(002432) turned over. On April 12, Andon Health Co.Ltd(002432) announced that benefiting from the growth of overseas sales revenue of covid-19 antigen detection kit products, the company expects the net profit in the first quarter of 2022 to reach 14-16 billion yuan. However, Andon Health Co.Ltd(002432) also realized that the performance growth brought by covid-19 epidemic prevention and control was not sustainable. From the perspective of Andon Health Co.Ltd(002432) aspect, the revenue brought by the kit gives the company more funds and resources to promote the development of its core strategy.
first quarter pre profit of 16 billion
“Net income of more than 150 million yuan per day” and “printing money” are comparable to the speed of Maotai… Andon Health Co.Ltd(002432) disclosure of the performance forecast for the first quarter of 2022 triggered a heated discussion in the market. According to the performance forecast, the net profit of Andon Health Co.Ltd(002432) 2022 in the first quarter is expected to reach 14-16 billion yuan, with a year-on-year increase of 3670743% – 4196563%.
Andon Health Co.Ltd(002432) made more money in the first quarter of 2022 than the sum of the past ten years. Calculated by 90 days in the first quarter, Andon Health Co.Ltd(002432) made more than 150 million yuan per day. According to the financial report data, the net profit of Andon Health Co.Ltd(002432) in 20122021 was 069.8 million yuan, – 083.5 million yuan, 10.2 million yuan, – 151 million yuan, 14.5 million yuan, – 166 million yuan, 12.7 million yuan, 66 million yuan, 242 million yuan and 913 million yuan respectively, totaling about 940 million yuan.
Covid-19 antigen detection kit is the main reason for the great increase of Andon Health Co.Ltd(002432) performance Andon Health Co.Ltd(002432) said in the announcement that the local demand for covid-19 antigen detection kit products has increased significantly due to the development of the epidemic in the United States. During the reporting period, ihealth US subsidiary of the company sold ihealth covid-19 antigen detection kit products through its own channels and Amazon platform, and signed major contracts and orders with customers. The increase in sales revenue of this product has made an important contribution to the company’s performance during the reporting period.
According to incomplete statistics, Andon Health Co.Ltd(002432) currently has a total of US $2.108 billion in orders. In November 2021, Andon Health Co.Ltd(002432) covid-19 antigen detection kit won the emergency use authorization of the U.S. Food and drug administration. According to an announcement in January 2022, Andon Health Co.Ltd(002432) has signed orders of US $1.609 billion (about RMB 10.226 billion) with the New York State Department of health, the New York State non-profit organization, the Executive Office of the Massachusetts Federal Department of health and human services, etc.
However, Andon Health Co.Ltd(002432) covid-19 antigen detection kit has not been approved in the Chinese market. As of April 2, the State Food and drug administration has approved 24 covid-19 virus antigen detection reagent products, of which Andon Health Co.Ltd(002432) .
With regard to the progress of product listing application in China and other issues, the reporter of Beijing business daily contacted Andon Health Co.Ltd(002432) aspects, and no more reply has been received as of press time.
deduction of non net profit, which has suffered losses for seven consecutive years
The performance of Andon Health Co.Ltd(002432) which has been hovering on the edge of ST has not received much attention before. In 2010, Andon Health Co.Ltd(002432) landed on Shenzhen Stock Exchange and became the first listed enterprise in China’s sphygmomanometer industry. On the basis of traditional hardware such as sphygmomanometer and blood glucose meter, Andon Health Co.Ltd(002432) promotes the “O+O” mode of diabetes care and the two core strategies for the launch of the new retail platform.
Diabetes management is the starting point of Andon Health Co.Ltd(002432) ‘s implementation of the Internet plus medical core strategy. The company takes mobile intelligent medical devices as the entrance, takes the Internet as the carrier and technical means, and establishes a doctor centered care team, extending the management and diagnosis of chronic diseases from the hospital to the hospital. Diabetes diagnosis and treatment “O+O” new mode has been accelerated by Andon Health Co.Ltd(002432) in China and the United States.
However, the competition of traditional household medical products is fierce, and the payback period of the “O+O” mode of diabetes care in the Internet healthcare industry is long. Andon Health Co.Ltd(002432) ‘s net profit in the past seven years (20132019 years) has always been negative, and its performance has been under pressure for a long time.
Excessive investment in internet medical treatment is the reason for the loss given by Andon Health Co.Ltd(002432) in an interview with the media. In the ten years of exploration, Andon Health Co.Ltd(002432) has established cooperation with China in 62 hospitals in more than 40 cities, expanding the new O+O diabetes care model to nearly 120 hospitals in more than 40 City, including No.1 Hospital of Peking University, city, Chaoyang Hospital, etc.
Covid-19 antigen detection reagent product has brought strong cash flow to Andon Health Co.Ltd(002432) company Andon Health Co.Ltd(002432) said publicly that with the revenue of the kit, the company has more funds and resources to accelerate the development of the two core strategies.
several companies’ performance pre increase
In addition to Andon Health Co.Ltd(002432) , the performance of Hangzhou Alltest Biotech Co.Ltd(688606) , Zhejiang Orient Gene Biotech Co.Ltd(688298) , Hangzhou Biotest Biotech Co.Ltd(688767) and other companies has been greatly affected by covid-19 nucleic acid / antigen detection reagent.
Hangzhou Alltest Biotech Co.Ltd(688606) ‘s covid-19 antigen (saliva) rapid detection reagent obtained the European ce1434 self-test Certificate in May 2021 Hangzhou Alltest Biotech Co.Ltd(688606) it is estimated that benefiting from the steady growth of covid-19 testing business orders, the company will realize a net profit of 1.03-1.19 billion yuan in the first quarter of 2022, with a year-on-year increase of 585.4% – 691.9%.
According to the Zhejiang Orient Gene Biotech Co.Ltd(688298) 2021 performance bulletin, New Coronavirus’s rapid detection reagent (including family self testing) continues to be put into the epidemic prevention business, and its sales performance in Europe continues to increase substantially. The company expects to achieve net profit of 4 billion 777 million yuan, an increase of 184.8% over the previous year.
However, such performance is unsustainable. According to Wang Chikun, an independent economist and financial commentator, the performance of relevant enterprises has increased greatly, which is affected by the demand, and the covid-19 epidemic prevention demand has derived the testing market. With the gradual popularization of covid-19 vaccine, the epidemic situation will be effectively controlled, and the derived demand market will shrink greatly.
Chen Wenming, founder of Zhejiang Xiaode law firm, believes that the performance growth brought by covid-19 epidemic prevention and control is sporadic, and there is a risk of unsustainability in the high growth of future performance. If the epidemic situation is effectively controlled, the sales of covid-19 testing reagents and related products of the company will decline.
